Showing results (191-200 of 2,560) with videos related to
Sort By:
Pageof 256
Diabetes & Metabolism|May 5, 2016
Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?G Targher, G Marchesini, C D ByrneThe Lancet. Gastroenterology & Hepatology|August 19, 2023
NASH drug treatment development: challenges and lessonsHerbert Tilg, Christopher D Byrne, Giovanni TargherThe Lancet. Gastroenterology & Hepatology|May 7, 2021
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approachGiovanni Targher, Herbert Tilg, Christopher D ByrneGut|April 24, 2020
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implicationsGiovanni Targher, Christopher D Byrne, Herbert TilgThe Journal of the Acoustical Society of America|February 12, 1998
Auditory localization, detection of spatial separateness, and speech hearing in noise by hearing impaired listenersW Noble, D Byrne, K Ter-HorstJournal of Public Health Medicine|October 5, 2001
Winter excess morbidity: is it a summer phenomenon?S J Watkins, D Byrne, M McDevittHospital Practice (1995)|May 18, 2010
Intensive insulin therapy in the intensive care unit, hypoglycemia, and cardiovascular mortalityOmar Rana, Christopher D Byrne, Kim GreavesCurrent Diabetes Reports|March 15, 2017
Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and PathogenesisP Wainwright, E Scorletti, C D ByrneThe Lancet. Gastroenterology & Hepatology|January 9, 2023
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver diseaseGiovanni Targher, Alessandro Mantovani, Christopher D ByrneExpert Review of Gastroenterology & Hepatology|December 3, 2020
A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLDYusuf Yilmaz, Christopher D Byrne, Giovanni MussoPageof 256